My 2 cents on $TRXC -> Versatility!

Before you read on, please be aware that the analysis below is my opinion only and may include flawed assumptions and inaccuracy of logic; therefore, caveat emptor applies here.

Last week, upon reflecting on CEO Pope’s opening narrative of their successful 2017 accomplishments, it dawned on me (aka my 2 cents) that Senhance, for all intent and purpose, is designed and created to counter the limitation of the Da Vinci’s design.  The most obvious difference is the separation of the arms.  Senhance has individual arms that are independent of each other. Unlike the Da Vinci, each Senhance arm has its own separate control base that is not mechanically tethered to a central body.  From a common sense perspective, anything that tether to the core pivotal base mechanically will have limitation in the range of movements. It’s like a dog chain that limit the range of the dog movements.

When each robotic arm is free and clear to be placed anywhere in the operating room, versatility is created.  Sometimes, a picture or video can show more than words can describe.  So, let’s take a look at versatility!

Below is the video titled, “Senhance Robotic Inguinal Hernia Repair – Dr Dietmar Stephan – St. Marien-Krankenhaus Siegen

Below is a screenshot from the video above:TRXC_SenhanceHerinaSee how relaxed and comfortable the caretakers were in surrounding the patient without an octopus of robotic arms dangling from above.  The Senhance arms were unobtrusive and easier to work with. That’s versatility!

Below is another screenshot from the above video at 06:23 min. Go to the time frame in the video and you can see hybrid surgery in action. TRXC_SenhanceHerina2The above screen showed that Senhance instrument was being removed (blue) from the trocar while the manual lap tool (white handle) was being prepped to go to the trocar.  This trocar compatibility as well as the independent arms concept, per my 2 cents, provided clues that Senhance was created and designed to offset the limitation of the Da Vinci’s robotic surgical system.  In other words, it’s my humble opinion that the Senhance is what the laparoscopic market has been waiting for.  And it is now approved by the FDA.  Therefore, I’m betting that Senhance will be adopted by the laparoscopy market.  Because we are still too early in the game (only about 5 months after FDA approval), the sign of tsunami has yet to reflect itself on the ocean wave. But by gosh! it’s COMING!

Has anyone seen this video from 2017 AAGL yet?

If not, below are a series of screenshots from the video that highlighted some key points…

TRXC_SenhanceHerina3

TRXC_SenhanceHerina4

TRXC_SenhanceHerina5

TRXC_SenhanceHerina6

TRXC_SenhanceHerina7

TRXC_SenhanceHerina8

TRXC_SenhanceHerina9

TRXC_SenhanceHerina10After looking at the above screenshots, isn’t it obvious the Senhance is designed specifically for the laparoscopy market?

How ’bout this one below, anyone see this abstract yet?

TRXC_SenhanceHerina11

Below is a line by line breakdown from the yellow highlighted area:

  1. Initial experience with the Senhance system as the first installation in Germany shows that
    1. it is suitable for surgery in general and for visceral surgery in particular
    2. Application is safe due to the unproblematically quick changeover to normal laparoscopy
    3. easy to integrate due to he very short system integration times (docking times)
  2. Since it is a laparoscopic-based system, following an integration program will enable:
    1. experienced laparoscopic surgeons to very quickly manage more complex procedures
  3. Due to lower costs:
    1. introducing robotic surgery starting with simple and standardized procedures is more feasible
  4. After the establishment of this second robotic system, future studies will have to specifically look at differences in surgical results and basic conditions of different robotic-assisted systems.
  5. This paper documents:
    1. the decision-making process of a hospital towards the integration of a robotic system
    2. the selection criteria used
    3. demonstrating the planning and execution process during the introduction of the system into clinical routine.

Notice item #4, Da Vinci surgical results will now be compared against the Senhance in future studies.  Imagine when the results favor the Senhance!?!

I don’t know about you, but the more I researched on Senhance, the more I find it very difficult to believe that it won’t be adopted by the laparoscopy market.  After all, per my 2 cents, the Senhance’s

  • independent arms
  • haptic feedback
  • eye-tracking video controller
  • reusable instruments (5mm & 3mm)
  • hybrid set-up
  • fast docking time
  • Cost effective

offer the most flexibility any laparoscopic surgeons can hope for.  And that is V E R S A T I L I T Y !!

Don’t forget, all the above are my opinion only!

Good Luck and may fortune blesses all TRXC investors.

My 2 cents.

From my camera:

019

 

 



Categories: Daily trading Journal, trading journal

Tags: ,

1 reply

Trackbacks

  1. Weekly thought on $AEMD, $AMRN, $IBIO, $LRAD, TRXC – Trading my two cents

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: